Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Women who use vaginal estrogen to manage early menopause after treatment for endometrial cancer may not have an increased risk for recurrence.

Women who previously had endometrial cancer and used vaginal estrogen therapy did not have higher risk for cancer recurrence than those who did not use vaginal hormone therapy, according to findings ...

Schonfeld SJ, Hartge P, Pfeiffer, RM, et al. An aggregated analysis of hormonal factors and endometrial cancer risk by parity. Cancer 2012 Dec 20. doi: 10.1002/cncr.27909. [Epub ahead of print] It is ...

Despite the increased incidence of endometrial cancer in younger women, there is limited research regarding the safety of local, low-dose vaginal estrogen therapy (ET) for survivors. A new study ...

In January, the American Cancer Society reported that for the first time women younger than 50 had a higher cancer incidence rate than men. Based on 2023 data, cancer incidence rates among women under ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy. The low response rates underscore a significant clinical need to ...

Rina-S has received FDA breakthrough therapy designation for advanced endometrial cancer after standard treatments fail, based on promising Phase 1/2 trial results. The RAINFOL-01 trial showed ...

Uterine serous carcinoma (USC) is an aggressive histological subtype of endometrial cancer that frequently presents with early extrauterine spread, often without uterine symptoms. We report a ...